Leonlimab (PRO 140) Phase II clinical trial program for the treatment of new coronary pneumonia obtains IND

CytoDyn, a biotech company that develops leronlimab (PRO 140) (CCR5 antagonist with the potential for multiple indications) and today announced that it has submitted a research application (IND) to the FDA for a Phase II clinical trial of leronb (PRO 140) to verify the effectiveness and safety of the treatment of THE COLIMAlima (PRO 140) for complications of CODilima(140)early studies have shown that Leronlimab inhibits the migration of Treg to inflammatory areas, and Tregs inhibits the innate immune response to pathogensMost importantly, macrophage migration and the release of inflammatory cytokines, including TNF, are responsible for severe lung damage in some patients, and the combination of Leronlimab and CCR5 alters macrophage migration and cytokine productionacute respiratory distress syndrome (ARDS) usually affects the entire lungs, while common pneumonia usually affects only a portion of the lungs"We believe that leronlimab can reduce the inflammation that causes ARDS, potentially reducing mortality in patients with COVID-19," said DrNader Pourhassan, President and CEO of CytoDyn